

## NEWS RELEASE

### **CORDLIFE INKS STRATEGIC ALLIANCE AGREEMENTS WITH CORDLABS ASIA TO CO-OPERATE IN THE PROVISION OF SERVICES RELATED TO CORD TISSUE BANKING**

- ***Cordlife to widen Group's suite of quality services in existing and new geographical regions***
- ***Geographical scope of the strategic alliance with Cordlabs Asia to extend to Singapore, Hong Kong, Malaysia, Indonesia, Philippines, Thailand and India***

**Singapore, February 25, 2013 – Cordlife Group Limited** (“Cordlife”, and together with its subsidiaries, the “Group”), the leading cord blood and tissue banking service provider, today announced that it has entered into agreements (the “SAAs”) with CordLabs Asia Pte. Ltd. (“CAP”), a subsidiary of CellResearch Corporation Pte. Ltd. (“CellResearch Corporation”), in which both parties will co-operate in the provision of human postnatal umbilical cord tissue storage, culturing services and training, and the transfer of the know-how in relation to such services.

It was previously disclosed in Cordlife's prospectus dated 21 March 2012 that the strategic alliance agreement (the “2010 SAA”) dated 11 February 2010 between Cordlife, CellResearch Corporation and CordLabs Pte. Ltd., which was assigned to Cordlife Stem Cell Technology Limited on 5 April 2011, will expire in February 2013 and upon such expiration, the Company intends to enter into a similar agreement directly with CellResearch Corporation. The SAAs were entered into by the Company with CAP in connection with the expiration of the 2010 SAA.

*The initial public offering of Cordlife Group Limited's shares was sponsored by PrimePartners Corporate Finance Pte. Ltd. (“Issue Manager”). The Issue Manager assumes no responsibility for the contents of this News Release.*

Under the arrangement, CAP, which has been authorised by CordLabs Pte. Ltd. to use and exploit stem or progenitor cells derived from human postnatal umbilical cord tissue for banking purposes only (“CRC Technology”), will provide services relating to tissue verification and biomarker testing using CRC Technology to Cordlife and its customers in Singapore, Hong Kong, Malaysia, Indonesia, Philippines and India on an exclusive basis, and in Thailand on a non-exclusive basis, for future culturing and use of cord tissue for therapeutic and/or other purposes. Cordlife clients will also be admitted into the Global Cord Registry which is a database for licensees of the patented cord tissue technology. Cordlife, on the other hand, will take the lead in collection, preparation and storage of cord tissue in these countries.

The SAAs shall be effective for an initial period of three years (“Initial Term”), with an automatic extension of an additional four years if certain conditions are met. CAP has also granted Cordlife a right of first refusal for a period of four years after the Initial Term should CAP at any time within such period wish to enter into any similar strategic alliance or co-operation arrangement or agreement with any third party.

CellResearch Corporation is a leading stem cell research and development company founded in 2002, which provides high quality primary cell strains, culture media and research service support to researchers and corporations the world over.

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife, said: “We are pleased with this strategic collaboration which will enable us to broaden our service offering into cord tissue banking. At the same time, we will be able to expand our geographical coverage in Asia through the bundling of both parties’ services.

“We view this as highly complementary to our respective strengths; Cordlife, in tissue banking and storage, and CAP, in the culturing of cord tissue for therapeutic and other purposes using CRC Technology. As a leading stem cell research and development company, CAP is a good fit with Cordlife’s culture, which places a strong emphasis on high standards of quality assurance for our customers.



“Regionally, in Hong Kong, our provision of umbilical cord tissue banking service, introduced in March 2011, has been met with good market acceptance and we are pleased that we will be offering this complementary service to more Asian countries.

“With this latest corporate development, coupled with the recent move into our new and larger facility at Yishun, A’Posh Bizhub, we believe that this will enable us to further entrench our leadership position.”

This strategic alliance is not expected to have a material impact on the Group's financial performance for the financial year ending 30 June 2013.

#### **ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)**

Incorporated in May 2001, Cordlife Group Limited is an award-winning and established cord blood and tissue banking service provider. Amongst the first private cord blood banks in Asia, the Group has established a dominant market leader position in Singapore\*. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks.

The Group collects, processes, tests, cryopreserves and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to preserve their child's cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child's umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways.

*\*According to the industry data in the Company's prospectus dated March 21, 2012*

Cordlife's business model, which allows customers to opt for a one-time lump sum payment, or annual payments until the child reaches maturity (21 years old in Singapore and 18 years old in Hong Kong), provides the Group with a stable pool of recurring cash flow.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical, Parkway East Hospital and Raffles Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 20% share in Shandong Cord Blood Bank.

Cordlife was amongst the first cord blood banks in Asia to be accredited by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7\*\*. In October 2012, Cordlife was awarded the prestigious SIAS Investors' Choice Awards as runner-up in the "Most Transparent Company Award 2012" New Issues Category.

*\*\*Awarded to Cordlife Hong Kong*

---

ISSUED ON BEHALF OF : Cordlife Group Limited  
BY : Citigate Dewe Rogerson, i.MAGE Pte Ltd  
1 Raffles Place  
#26-02 One Raffles Place  
SINGAPORE 048616  
CONTACT : Ms Dolores Phua / Ms Chelsea Phua  
DURING OFFICE HOURS : 6534-5122 (Office)  
AFTER OFFICE HOURS : 9750-8237 / 9667-5837 (Handphone)  
EMAIL : [dolores.phua@citigatedrimage.com](mailto:dolores.phua@citigatedrimage.com) /  
[chelsea.phua@citigatedrimage.com](mailto:chelsea.phua@citigatedrimage.com)

---

022/13/002/CGL

February 25, 2013